AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Xeris Pharmaceuticals Inc (NASDAQ:XERS)
7.74 USD
+0.050 0.650%Sponsored Reports
Loading...
| Previous Close (in USD) | 7.69 |
|---|---|
| Change | +0.050 0.650% |
| 52 W H/L (in USD) | 3.260/1.460 |
| EBITDA (in USD) | -32.686M |
| PE Ratio | -- |
| Volume | 2550098 |
| Diluted Eps TTM | -0.47 |
| Total Assets (in USD) | 322.602M |
|---|---|
| Total Liabilities (in USD) | 329.384M |
| Revenue TTM (in USD) | 171.356M |
| Cash (in USD) | 67.449M |
| Market Cap (in USD) | 284.652 M |
| Revenue Per Share TTM | 1.237 |
| Gross Profit TTM (in USD) | 87.614M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
180 North LaSalle Street, Chicago, IL, United States, 60601
844 445 5704
Employees: 377
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Paul R. Edick | Chairman & CEO | 1956 |
| 2. | Mr. John P. Shannon | Pres & COO | 1962 |
| 3. | Ms. Beth P. Hecht J.D. | Chief Legal Officer & Corp. Sec. | 1964 |
| 4. | Dr. Steven J. Prestrelski MBA, Ph.D. | Co-Founder & Chief Scientific Officer | 1964 |
| 5. | Mr. Steven M. Pieper | Chief Financial Officer | 1977 |
| 6. | Ms. Allison Wey | Sr. VP of Investor Relations & Corp. Communications | NA |
| 7. | Dr. Kenneth E. Johnson Pharm. D., Pharm.D. | Sr. VP of Global Devel. & Medical Affairs | 1963 |
| 8. | Mr. Kevin McCulloch | Chief Commercial Officer | NA |
| 9. | Mr. John P. Shannon | President & COO | 1962 |
| 10. | Ms. Beth P. Hecht J.D. | Chief Legal Officer & Corporate Secretary | 1964 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.270 0.562% | 47.72 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.003 0.005% | 47.8 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+8.310 1.691% | 495.83 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-1.090 0.172% | 635.99 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -96.084M | -122.725M | -91.25M | -126.038M | -60.08M |
| Minority Interest | - | - | - | - | - |
| Net Income | -94.66M | -122.725M | -91.14M | -125.58M | -60.08M |
| Selling General Administrative | 137.745M | 125.718M | 73.732M | 63.061M | 21.113M |
| Gross Profit | 87.614M | 36.272M | 10.827M | 1.119M | 2.423M |
| Reconciled Depreciation | 12.668M | 1.879M | 1.467M | 1.078M | 0.32M |
| Ebit | -81.94M | -115.156M | -83.546M | -122.38M | -58.051M |
| Ebitda | -71.097M | -114.606M | -80.581M | -119.567M | -57.731M |
| Depreciation And Amortization | 10.843M | 0.55M | 2.965M | 2.813M | 0.32M |
| Operating Income | -81.94M | -115.156M | -83.546M | -122.38M | -59.344M |
| Other Operating Expenses | 192.188M | 164.746M | 103.701M | 125.102M | 61.809M |
| Interest Expense | 15.325M | 7.18M | 10.66M | 7.163M | 2.545M |
| Tax Provision | -1.424M | 0M | -0.11M | -0.458M | - |
| Interest Income | 2.578M | 0.313M | 2.965M | 2.813M | 1.613M |
| Net Interest Income | -12.747M | -6.867M | -7.695M | -4.35M | -0.932M |
| Income Tax Expense | -1.424M | -0.11M | -0.11M | -0.458M | 1.809M |
| Total Revenue | 110.248M | 49.59M | 20.155M | 2.722M | 2.465M |
| Total Operating Expenses | 169.554M | 151.428M | 94.373M | 123.499M | 61.767M |
| Cost Of Revenue | 22.634M | 13.318M | 9.328M | 1.603M | 0.042M |
| Total Other Income Expense Net | -14.144M | -7.569M | -7.704M | -3.658M | 0.196M |
| Net Income From Continuing Ops | -94.66M | -122.725M | -91.14M | -125.58M | -60.08M |
| Net Income Applicable To Common Shares | -94.66M | -122.725M | -91.14M | -125.58M | -60.08M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 322.602M | 344.522M | 304.361M | 159.151M | 108.987M |
| Intangible Assets | 109.764M | 3.992M | 131.45M | - | - |
| Other Current Assets | 5.778M | 9.287M | 4.589M | 3.196M | 4.119M |
| Total Liab | 329.384M | 299.335M | 209.13M | 125.39M | 94.551M |
| Total Stockholder Equity | -6.782M | 45.187M | 95.231M | 33.761M | 14.436M |
| Other Current Liab | 80.133M | 2.658M | 70.116M | 25.09M | 21.735M |
| Common Stock | 0.014M | 0.014M | 0.013M | 0.006M | 0.003M |
| Capital Stock | 0.014M | 0.014M | 0.013M | 0.006M | 0.003M |
| Retained Earnings | -617.025M | -554.77M | -460.11M | -337.385M | -246.245M |
| Good Will | 22.859M | 120.607M | 22.859M | - | - |
| Other Assets | - | 4.73M | 0.829M | 0.232M | 0.42M |
| Cash | 67.449M | 121.966M | 67.271M | 37.598M | 19.519M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 95.193M | 73.621M | 79.04M | 28.207M | 27.338M |
| Current Deferred Revenue | - | 64.777M | - | - | - |
| Net Debt | 161.742M | 76.091M | 20.796M | 49.423M | 38.786M |
| Short Term Debt | 3.495M | 1.58M | 1.58M | - | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 229.191M | 198.057M | 88.067M | 87.021M | 58.305M |
| Other Stockholder Equity | 610.254M | 599.966M | 555.359M | 371.134M | 260.635M |
| Property Plant Equipment | - | 9.508M | 6.627M | 6.707M | 7.853M |
| Total Current Assets | 156.264M | 186.818M | 142.596M | 152.212M | 87.483M |
| Long Term Investments | - | - | - | 0M | 13.231M |
| Short Term Investments | 5.002M | 0M | 35.162M | 96.19M | 56.03M |
| Net Receivables | 39.197M | 30.83M | 17.456M | 6.875M | 5.639M |
| Long Term Debt | 190.932M | 187.075M | 88.067M | 87.021M | 58.305M |
| Inventory | 38.838M | 24.735M | 18.118M | 8.353M | 2.176M |
| Accounts Payable | 11.565M | 4.606M | 8.924M | 3.117M | 5.603M |
| Accumulated Other Comprehensive Income | -0.025M | -0.023M | -0.031M | 0.006M | 0.043M |
| Non Currrent Assets Other | 4.54M | 4.73M | 0.829M | -12.999M | 0.42M |
| Non Current Assets Total | 166.338M | 157.704M | 161.765M | 6.939M | 21.504M |
| Capital Lease Obligations | 38.259M | 10.982M | - | - | - |
| Long Term Debt Total | - | - | - | 87.021M | 58.305M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 34.461M | 60.58M | -101.773M | -102.472M | -68.851M |
| Total Cashflows From Investing Activities | 34.461M | 97.964M | -27.405M | -2.383M | -68.261M |
| Total Cash From Financing Activities | 127.473M | 27.247M | 126.064M | 80.53M | 128.211M |
| Net Income | -94.66M | -122.725M | -91.14M | -125.58M | -60.08M |
| Change In Cash | 59.043M | 29.673M | 18.079M | -26.197M | 3.671M |
| Begin Period Cash Flow | 67.271M | 37.598M | 19.519M | 45.716M | 42.045M |
| End Period Cash Flow | 126.314M | 67.271M | 37.598M | 19.519M | 45.716M |
| Total Cash From Operating Activities | -102.891M | -95.535M | -80.558M | -104.346M | -56.279M |
| Depreciation | 12.668M | 1.879M | 1.467M | 1.078M | 0.32M |
| Other Cashflows From Investing Activities | - | - | - | -1.276M | -66.751M |
| Dividends Paid | -147.05M | -25.089M | -95.643M | 60.684M | - |
| Change To Inventory | -7.465M | -7.418M | -5.143M | -2.176M | 4.042M |
| Sale Purchase Of Stock | -0.468M | -0.534M | -0.063M | -4.465M | 98.325M |
| Other Cashflows From Financing Activities | 288.487M | 50.959M | 180.968M | 118.987M | 29.886M |
| Capital Expenditures | 0.524M | 1.085M | 0.377M | 1.107M | 1.51M |
| Change In Working Capital | -35.15M | 11.854M | -2.798M | 11.778M | 1.607M |
| Other Non Cash Items | 3.515M | 0.961M | 3.104M | 0.948M | 0.56M |
| Free Cash Flow | -103.415M | -96.62M | -80.935M | -105.453M | -57.789M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 4254957 |
| 2. | iShares Russell 2000 ETF | 2 years ago | 3104405 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 2117697 |
| 4. | Fidelity Small Cap Index | 2 years ago | 1364027 |
| 5. | CREF Stock R1 | 2 years ago | 1165530 |
| 6. | iShares Russell 2000 Growth ETF | 2 years ago | 1126062 |
| 7. | Fidelity Extended Market Index | 2 years ago | 830315 |
| 8. | State St Russell Sm/Mid Cp® Indx NL Cl C | 2 years ago | 807840 |
| 9. | Invenomic Institutional | 2 years ago | 630182 |
| 10. | MEDICAL BioHealth EUR Acc | 2 years ago | 587239 |
| 11. | Vanguard Russell 2000 ETF | 2 years ago | 494508 |
| 12. | State St Russell Sm Cap® Indx SL Cl I | 2 years ago | 477539 |
| 13. | SPDR® S&P Pharmaceuticals ETF | 2 years ago | 394638 |
| 14. | NT R2000 Growth Index Fund - NL | 2 years ago | 394086 |
| 15. | NT R2000 Index Fund - NL | 2 years ago | 378265 |
| 16. | BlackRock Extended Mkt Composite | 2 years ago | 376723 |
| 17. | BlackRock Extended Equity Market K | 2 years ago | 340339 |
| 18. | Schwab Small Cap Index | 2 years ago | 305453 |
| 19. | Lazard Rathmore Alternative EA Acc USD | 2 years ago | 302766 |
| 20. | NT R2000 Index Fund - DC - NL - 2 | 2 years ago | 300394 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 2 years ago | 10011391 |
| 2. | Vanguard Group Inc | 2 years ago | 7606242 |
| 3. | Caxton Corp | 2 years ago | 5113348 |
| 4. | MPM Oncology Impact Management LP | 2 years ago | 3847232 |
| 5. | Geode Capital Management, LLC | 2 years ago | 2892077 |
| 6. | Rosalind Advisors, Inc. | 2 years ago | 2820170 |
| 7. | State Street Corporation | 2 years ago | 2724126 |
| 8. | Millennium Management LLC | 2 years ago | 1695753 |
| 9. | Renaissance Technologies Corp | 2 years ago | 1381640 |
| 10. | Morgan Stanley - Brokerage Accounts | 2 years ago | 1221358 |
| 11. | Northern Trust Corp | 2 years ago | 1165363 |
| 12. | AQR Capital Management LLC | 2 years ago | 1141006 |
| 13. | Redmile Group, LLC | 2 years ago | 1046587 |
| 14. | D. E. Shaw & Co LP | 2 years ago | 707011 |
| 15. | Invenomic Capital Management, LP | 2 years ago | 604512 |
| 16. | Stonepine Capital Management Llc | 2 years ago | 598086 |
| 17. | Tudor Investment Corp Et AL | 2 years ago | 573186 |
| 18. | Ameriprise Financial Inc | 2 years ago | 520121 |
| 19. | Goldman Sachs Group Inc | 2 years ago | 517378 |
| 20. | Nuveen Asset Management, LLC | 2 years ago | 424972 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...